L-Tetrahydropalmatine: Uses, Effects, and Safety Profile

L-Tetrahydropalmatine (l-THP) is a plant-derived alkaloid that acts primarily by blocking dopamine receptors in the brain, giving it a pharmacological profile that overlaps with some prescription psychiatric medications but comes packaged in herbal supplements and traditional medicine preparations. Found naturally in plants like Corydalis yanhusuo and several Stephania species, l-THP has drawn research interest for pain relief, addiction treatment, and sedation, while carrying safety concerns that most supplement labels fail to mention.

Where L-THP Comes From

L-THP belongs to a family of chemicals called isoquinoline alkaloids, and it occurs naturally in several plants used in traditional Asian medicine. The most common source is Corydalis yanhusuo, a flowering plant in the poppy family (Papaveraceae) that has been used in China, Japan, and Korea for centuries. Other plant sources include Stephania epigaea and Phellodendron chinense.¹ In traditional Chinese medicine, Corydalis rhizome (the dried tuber of Corydalis yanhusuo) is typically processed with vinegar before use, a method that appears to increase absorption of THP into various organs including the brain.²

Today, you can find l-THP sold as a standalone supplement or as an ingredient in Corydalis extracts marketed for sleep, pain, and relaxation. The compound is sometimes labeled as “corydalis extract” without specifying l-THP content, which creates a quality-control problem we will return to later.

How It Works in the Brain

The defining feature of l-THP is that it blocks dopamine receptors. It acts as an antagonist at D1, D2, and D3 dopamine receptors, meaning it sits on these receptors and prevents dopamine from activating them.³ It also interacts with alpha-adrenergic receptors and serotonin receptors, broadening its effects beyond pure dopamine blockade.⁴

This receptor profile matters because dopamine is central to reward, motivation, pain processing, and movement. Blocking dopamine receptors is also what conventional antipsychotic drugs do, which is why l-THP shares some of their therapeutic effects and some of their risks. The key difference is that l-THP’s binding affinity at these receptors is described as “modest” compared to prescription dopamine antagonists, which may explain why its effects tend to be milder but also why high doses or drug interactions could push them into uncomfortable territory.⁵

Once swallowed, l-THP crosses the blood-brain barrier readily. In rat studies, brain concentrations peaked about 30 minutes after an oral dose, and the ratio of brain-to-blood levels consistently exceeded 1, meaning the compound concentrates in brain tissue rather than staying in the bloodstream.⁶ Once in the body, l-THP is broken down primarily by CYP3A4, CYP1A2, CYP2D6, and CYP2C19 liver enzymes, and it produces at least one active metabolite called l-isocorypalmine.⁷

Pain Relief

Pain management is one of the traditional uses of Corydalis, and modern animal research supports the idea that l-THP has genuine analgesic properties. In mouse models of both inflammatory and nerve-injury pain, l-THP reduced pain sensitivity in a dose-dependent manner without impairing motor function, an important distinction because it suggests the animals were not simply too sedated to respond.⁸ When researchers blocked D1 dopamine receptors in these animals, the pain-relieving effect disappeared, pointing to dopamine-mediated analgesia as a core mechanism.

The story gets more complex than just dopamine, though. Separate research found that l-THP also modulates a receptor called sigma-1 in the spinal cord, and that combining l-THP with a sigma-1 blocker produced a synergistic pain-relieving effect that was stronger than either compound alone.⁹ More recent work in rats with nerve injury showed that l-THP relieved both mechanical and thermal pain, and that it appeared to work partly by tamping down inflammatory signaling pathways in the nervous system.¹⁰

An important caveat: all of this pain research is in rodents. No large randomized clinical trials have tested l-THP specifically as a painkiller in humans, so the effective dose and clinical significance for chronic pain patients remain unknown. People who buy Corydalis supplements for back pain or fibromyalgia are essentially extrapolating from animal data.

Addiction and Craving Reduction

The most clinically developed use of l-THP is in addiction treatment, particularly for cocaine and heroin. Because dopamine signaling is at the heart of drug reward and craving, a mild dopamine antagonist that people can tolerate daily is an attractive concept. The research here moves from animal models to at least some human data.

In rats trained to self-administer cocaine, l-THP reduced the amount of cocaine the animals sought and also blunted the reinstatement of cocaine-seeking behavior after a period of abstinence, at doses that did not simply shut down the animals’ ability to move or eat.¹¹ Similar results were seen with heroin: l-THP reduced heroin self-administration and blocked heroin-triggered relapse behavior without impairing locomotion at lower doses.¹²

In humans, a small pilot study tested l-THP in heroin users going through post-acute withdrawal. After four weeks of treatment, the l-THP group showed meaningful improvement in physical symptoms, mood, insomnia, and drug craving compared to a placebo group. At a three-month follow-up, those who stayed on l-THP for at least the first two weeks had an abstinence rate of about 48%, compared to roughly 15% in the placebo group.¹³ Those numbers are encouraging but come from a small, unblinded pilot, so they should be taken as promising signals rather than proof.

A separate randomized, double-blind trial looked at whether l-THP was safe to give to active cocaine users. Twenty-four men received either l-THP at 30 mg twice daily or a placebo for about three and a half days, followed by a cocaine challenge. The l-THP was well tolerated, did not alter cocaine’s effects on heart rate or blood pressure, and the rate of side effects was essentially the same in both groups.¹⁴ This study was designed to establish safety and dosing, not to measure whether l-THP reduces cocaine use, so the therapeutic question remains open.

Sleep and Sedation

Many people encounter l-THP through Corydalis-based sleep supplements, and the sedative effect is real. The compound’s partial agonism at D1 receptors and antagonism at D2 receptors give it a pharmacological basis for promoting drowsiness.¹⁵ Early pharmacological studies from the 1960s confirmed that l-THP produced sedation in mice at the level of reticular formation signaling, the brain’s arousal center, without altering sensory responses in the cortex.¹⁶

The practical question for someone considering a Corydalis supplement for sleep is how this compares to other options. L-THP’s sedation is mechanistically closer to an antipsychotic than to melatonin or a benzodiazepine. That means it can work, but the side-effect profile is different and potentially more serious at higher doses, including the movement-related symptoms discussed below. Casual use for occasional sleeplessness is a different risk calculation than nightly use at increasing doses, and the lack of standardized dosing in supplements makes this a murky area.

Neuroprotection Research

A separate line of animal research has investigated l-THP’s potential to protect brain tissue after stroke. In rats subjected to blocked blood flow to the brain followed by reperfusion (restoring flow, which paradoxically causes its own wave of damage), pretreatment with l-THP reduced the size of the damaged area, improved neurological outcomes, and decreased brain swelling.¹⁷ The mechanism appears to involve l-THP reducing the permeability of the blood-brain barrier after injury by inhibiting enzymes and signaling pathways that would otherwise break down the barrier’s structural integrity.¹⁸

This research is entirely preclinical, and neuroprotection after stroke has a long history of compounds that look excellent in rodents and then fail in humans. Still, the findings add to the overall picture of l-THP as a compound with broad central nervous system activity, not just a simple sedative.

Liver Safety

The most concerning safety signal for l-THP involves the liver. Clinical reports have linked both l-THP and Corydalis-containing products to cases of drug-induced liver injury. In a published case series, two patients developed abnormal liver enzyme levels while taking a Corydalis-based sleep supplement. One was asymptomatic but had a clear pattern of enzyme elevation that tracked with starting, stopping, and restarting the supplement. The other developed symptoms consistent with liver dysfunction that resolved when the supplement was discontinued.¹⁹

Laboratory work supports a biological mechanism for this toxicity. In both mouse liver cells and a human liver cell line, l-THP triggered programmed cell death (apoptosis).²⁰ Traditional processing methods seem to partially account for this risk: vinegar processing of Corydalis rhizome has been associated with reduced liver damage and muscle tremors in mice compared to unprocessed material.²

For anyone using Corydalis supplements regularly, periodic liver function testing is worth discussing with a doctor, particularly if you have pre-existing liver conditions or take other medications metabolized by the liver.

Overdose and Acute Toxicity

Acute overdose cases have been documented. A report of nine adults who overdosed on tetrahydropalmatine found that all experienced mild neurological disturbances but recovered quickly. Blood levels of THP in the five cases where it was measured ranged up to 1.2 mg/L. The compound was metabolized rapidly and excreted as metabolites in urine.²¹ The fact that recovery was quick and the neurological effects were described as mild suggests a relatively wide margin between a typical dose and a lethal one, but “mild neurological disturbance” after an overdose of a dopamine antagonist could include things like excessive sedation, confusion, or movement abnormalities that are quite unpleasant in the moment.

Because l-THP blocks dopamine receptors, high or prolonged doses carry at least a theoretical risk of extrapyramidal symptoms, which are the movement side effects associated with antipsychotic drugs: stiffness, tremor, restlessness, and in rare cases involuntary movements. This risk has not been well characterized for l-THP specifically at typical supplement doses, but it is a pharmacologically predictable consequence of strong dopamine blockade, and it is worth being aware of if you notice unusual stiffness or restlessness after taking Corydalis products.

Drug Interactions Worth Knowing About

L-THP’s metabolism through several cytochrome P450 enzymes creates real potential for drug interactions. The compound is broken down by CYP3A4 and CYP2D6 among others, and drugs that inhibit these enzymes can dramatically increase l-THP levels in the body. In a rat study, pre-treatment with a CYP3A4 inhibitor (ketoconazole) increased total blood exposure to l-THP by more than four-fold, while a broad CYP inhibitor increased it more than eleven-fold.²²

The interaction runs both ways. THP itself acts as a mechanism-based inhibitor of CYP2D6, meaning it does not just temporarily block the enzyme but inactivates it, requiring the body to produce new enzyme before normal activity resumes.²³ CYP2D6 processes a wide range of common medications including many antidepressants, beta-blockers, opioid painkillers, and some antihistamines. Taking l-THP alongside any of these could slow their breakdown and raise their blood levels unpredictably. This is not a theoretical concern reserved for unusual combinations; someone using a Corydalis sleep supplement who also takes an SSRI or a codeine-containing painkiller is walking into exactly this scenario without knowing it.

Why the L- and D- Forms Matter

Tetrahydropalmatine exists as two mirror-image forms: l-THP (levo, left-handed) and d-THP (dextro, right-handed). Most research and supplement use focuses on the l- form because it is the pharmacologically active one. The difference is not subtle. Classic pharmacological studies found that d-THP was essentially inactive as a sedative, while l-THP produced clear sedation and suppressed arousal signaling in the brain. In fact, d-THP sometimes did the opposite, facilitating cortical responses rather than dampening them.¹⁶

The two forms also differ in how they affect liver enzymes. In rat studies, d-THP inhibited CYP2D6 and CYP1A2, while l-THP inhibited CYP1A2 but induced CYP3A4 and CYP2C9.²⁴ Some Corydalis extracts contain a racemic mixture (both forms), while others are enriched in l-THP. The ratio matters for both efficacy and interaction risk, but supplement labels rarely specify which form or what proportion they contain.

The Schizophrenia Trial That Did Not Pan Out

Given that l-THP blocks dopamine receptors much like antipsychotic medications, researchers tested whether it could improve symptoms in people with schizophrenia when added to their existing treatment. The idea made pharmacological sense, but the trial found that l-THP failed to improve psychiatric symptoms as an add-on therapy.³ This result is instructive. L-THP’s “modest” receptor affinity may be enough to produce sedation and reduce craving, but not enough to meaningfully suppress the dopamine hyperactivity thought to drive psychotic symptoms. It helps calibrate expectations: l-THP is not a substitute for psychiatric medication, even though it hits some of the same receptors.

What Supplement Labels Leave Out

If you buy a Corydalis or l-THP supplement, a few practical gaps are worth noting. First, dosing is not standardized. The human addiction study used 30 mg of l-THP twice daily and found it well tolerated over a few days, but supplements vary widely in how much l-THP they deliver per capsule, and some list only the weight of raw Corydalis extract without specifying alkaloid content.¹⁴ Second, long-term safety in humans has not been established. The controlled trials lasted days to weeks, while many people use these supplements for months. Third, the hepatotoxicity signal and the CYP2D6 inhibition are not mentioned on any supplement label I have seen. People with liver disease, those taking medications processed by CYP2D6 or CYP3A4, and those using multiple herbal products simultaneously face compounding risks that no one is warning them about.

In countries where l-THP is used as an approved pharmaceutical ingredient (primarily China), it is dosed and monitored within a clinical framework. In Western markets, it exists in a regulatory gray zone as a dietary supplement, without the purity testing, interaction warnings, or dosing guidance that a prescription drug would require. That gap between pharmacological potency and regulatory oversight is the core tension of l-THP’s current status.